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Abstract
Purpose Ischemic stroke significantly contributes to morbidity and mortality in heart failure (HF). The risk of stroke increases
significantly, with coexisting atrial fibrillation (AF). An aggravating factor could be asymptomatic paroxysms of AF (so-called
silent AF), and therefore, the risk stratification in these patients remains difficult. This review provides an overview of stroke risk
in HF, its risk stratification, and stroke prevention in these patients.
Recent Findings Stroke risk stratification in HF patients remains an important issue. Recently, the CHA2DS2-VASc score,
originally developed to predict stroke risk in AF patients, had been reported to be a predictive for strokes in HF patients regardless
of AF being present. Furthermore, there are several independent risk factors (e.g., hypertension, diabetes mellitus, prior stroke)
described.
Summary Based on the current evidence, HF should be considered as an independent risk factor for stroke. The CHA2DS2-VASc
score might be useful to predict stroke risk in HF patients with or without AF in clinical routine. However, there is only a
recommendation for the oral anticoagulation use in patients with concomitant HF and AF, while in patients with HF and no AF,
individualized risk stratification is preferred. Current guidelines recommend to prefer non-vitamin Kantagonist anticoagulants
over warfarin.
Keywords Heart failure . Stroke . Silent atrial fibrillation . Risk stratification . Stroke prevention
Introduction
Heart failure (HF) is a frequent condition associated with di-
verse comorbidities such as cardiac arrhythmias, thromboem-
bolism, impaired renal function, and an increased mortality as
a result [1]. The prevalence of HF is approximately 1–2% of
the adult population in developed countries with a higher per-
centage (> 10%) in the population age > 70 years [1].
An increased stroke risk in HF patients has been described
in several studies [2]. Pathophysiologically, a predisposition to
thromboembolism is caused by abnormal blood flow, abnor-
mal vessel/chamber lining, and abnormal blood particles, also
referred to as Virchow’s triad [3]. Abnormal blood flow is
evident in patients with HF because of left ventricular systolic
dysfunction (LVSD) associated with left ventricular dilatation
and abnormal (slowed) blood flow [4]. Given the fact that HF
patients with preserved EF (HFpEF) also have an increased
stroke risk [5, 6], such patients also exhibit flow abnormali-
ties—apart from vessel wall changes (e.g., endothelial dys-
function) [7, 8] and abnormal blood constituents (e.g., platelet
function) [9].
Atrial fibrillation (AF) is the strongest independent risk
factor for stroke, followed closely by HF [10]. Of note, HF
and AF frequently coexist and exacerbate each other: while
AF occurs in more than half (57%) individuals with HF, HF is
present in over one third (37%) of AF patients. These results
had been shown in 1737 individuals with new AF and 1166
individuals with new HF from Framingham Heart Study [11].
Particularly, paroxysmal AF is mostly associated with stroke
in comparison to persistent AF [12]. Problematically, patients
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are often unaware of these (often asymptomatic) paroxysmal
AF attacks and remain underdiagnosed. Indeed, episodes of
silent AF are present in approximately one third of the total
population of patients with AF [13].
Given the high rates of hospitalization and lethality due to
stroke in HF patients, there is a major clinical interest in stroke
prediction. Several risk factors associated with an increased
stroke risk (e.g., advanced age, prior stroke, diabetes mellitus)
[14] have already been identified and were included into dif-
ferent risk models [15•]. The predictive value of the
CHA2DS2-VASc score, originally designed for stroke predic-
tion in AF patients, has also been shown in the HF population
[16••, 17].
While oral anticoagulation in AF is recommended depen-
dent on the CHA2DS2-VASc score, current HF guidelines do
not recommend oral anticoagulation for HF patients without
documented AF. Indeed, there is an explicit recommendation
for an oral anticoagulation only in patients with both HF and
AF.
In this review, we discuss the risk of stroke in HF patients,
distinguishing between HF with and without coexisting AF.
Second, we debate the role of silent AF in these patients and,
third, give an overview of risk stratification and therapy
approaches.
Search Strategy
Electronic searches of English literature were performed in the
PubMed database for relevant publications from 2000 to 2018
evaluating the risk of stroke in HF patients with and without
AF as well as the role of silent AF, possibilities of risk strat-
ification, and therapeutic implications. The following search
terms were used in this review: “heart failure” AND/OR
“stroke” AND/OR “atrial fibrillation” AND/OR “AF” AND/
OR “silent atrial fibrillation”AND/OR “epidemiology”AND/
OR “risk stratification”AND/OR “NOAC”AND/OR “warfa-
rin.” Articles were used when studies investigated
abovementioned aspects or reviewed the current state of re-
search of stroke in HF. Two authors (K.S. and J.K.) screened
all the studies for qualification by abstract screening and full-
text reviewing.
HF Epidemiology
Over 40 million individuals have HF, which is considered as
the second most important risk factor for stroke after AF [10,
18]. Of note, 10–24% of patients with stroke have HF, while
HF per se (without AF) appears to be the cause of stroke in 9%
in comparison to 15% for AF per se and 2% for both HF and
AF [19]. As mentioned above, analysis of Framingham Heart
Study patients (participants with new-onset AF (n = 1737)
and/or HF (n = 1166)) showed that AF occurs in more than
half (57%) of the individuals with HF; HF is presented in over
one third (37%) of AF patients [11]. Nevertheless, data
reporting the incidence of stroke in HF patients vary among
studies with designs and populations [20].
Several clinical trials—Warfarin/Aspirin Study in Heart
failure (WASH), HEart failure Long-term Antithrombotic
Study (HELAS), Warfarin and Antiplatelet Therapy in
Chronic Heart failure trial (WATCH), and Warfarin versus
Aspirin in Reduced Cardiac Ejection Fraction trial
(WARCEF)—investigating HF patients in sinus rhythm have
reported a low incidence of stroke in their populations
[21–23]. In the WATCH trial, the incidence of stroke ranged
from 0.4% in the warfarin group to 2.3% in the aspirin plus
clopidogrel group. In a community-based cohort of 630 pa-
tients, Witt et al. found that 16% of the HF patients (where
41% had AF) experienced an ischemic stroke [2]. Their stroke
risk was 17.4-fold increased within first 30 days after the
initial diagnosis and remained elevated during follow-up of
5 years [2]. In another study, Mujib reported an approximately
1% annual rate of stroke in HF patients with sinus rhythm,
which was higher than in general population (0.3%) [24] but
lower than in those with both HF and AF. The presence of HF
is associated with high mortality and hospitalization rates.
Indeed, stroke patients with HF have longer hospitalization
periods and a 2.0–2.5-fold higher mortality than patients with-
out HF [2]. Stroke risk in HF patients seems to depend on HF
severity: mild to moderate HF is associated with an annual
stroke risk of 1.5% [25, 26], while stroke risk in severe HF
approaches 4% [27].
Asmentioned, concomitant HF and AF are the cause of 2%
of all strokes. The overall rate of stroke in HF without AF
(1.6% per year) is about one third of that seen in AF without
HF (5%) [19]. Of note, AF type could play an important role
for the stroke occurrence in HF patients. However, the litera-
ture is controversial. On the one hand, persistent AF is de-
scribed to not increase stroke risk in contrast to paroxysmal
AF [12]. On the other hand, several studies reported an equal
risk of stroke for paroxysmal and persistent AF [28] or even
opposite results [29]. A meta-analysis including 18 papers
with 134,847 AF patients [30] showed that the stroke risk
was higher in patients with persistent AF with ORs of 0.75
(95% confidence interval (CI) 0.61–0.93) in studies with no
oral anticoagulants and 0.77 (95% CI 0.68–0.88) in studies
with oral anticoagulants in all patients. Nevertheless, it re-
mains unclear if AF type is an independent predictor of stroke
or predicated on a different patient profile regarding risk fac-
tors and comorbidities [31]. Patients with paroxysmal AF are
likely to be younger, with a lower prevalence of structural
heart disease, major comorbidities, and also have lower esti-
mated thromboembolic and bleeding risks [32]. Based on this
knowledge, it seems more reasonable that persistent AF has
the higher stroke risk. But paroxysmal AF remains often
Curr Heart Fail Rep
asymptomatic as well as undiagnosed and consequently un-
treated leading to a possible increased risk of cardioembolic
events [33].
Four randomized clinical trials investigating the effect of
non-vitamin K antagonist oral anticoagulants (NOACs)
anticoagulants (NOACs) in AF patients have presented
different data on the effect of concomitant HF and AF.
Whereas the Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation
(ARISTOTLE) study [34] and the Rivaroxaban versus
Warfarin in Nonvalvular Atrial Fibrillation (ROCKET
AF) study [35] could not find a significant difference in
risk rates for stroke in AF patients with and without HF,
the Effective aNticoaGulation with factor xA next
GEneration in Atrial Fibrillation–Thrombolysis In
Myocardial Infarction study 48 (ENGAGE AF TIMI 48)
trial found an increased risk for patients with both AF and
HF present [36]. In the Randomized Evaluation of Long-
Term Anticoagulation Therapy (RE-LY) trial, there was a
numerically higher incidence of stroke in patients with AF
and HF compared to AF without HF, but this was non-
significant after multivariable adjustment [37].
While both HF and AF are independent risk factors for
stroke, the coexistence of both diseases increased the risk even
more. Kang et al. reported a 3.5-fold increased risk for stroke
in HF-only patients, while patients with HF + AF had a five-
fold risk in stroke [38]. A more recent study did not find any
significant difference in stroke risk between HF patients with
or without AF (incidence = 2.6% patients with AF vs 2.8%
without AF) [39]. The presence of AF had been also attributed
to play a role in stroke etiology, as patients with both HF and
AF mostly experienced cardioembolic strokes regardless of
the HF etiology. Of note, patients with HF but without AF
have different stroke causes according to the HF etiology:
for example, patients with dilated cardiomyopathy or valvular
heart disease had more frequent cardioembolic strokes while
those with coronary artery disease/hypertension tended to ex-
perience atherosclerotic and lacunar strokes [40].
Heart Failure with Preserved Ejection Fraction
Most of prior studies investigated the stroke risk in patients
with HF and reduced ejection fraction (HFrEF); however, HF
with preserved EF (HFpEF) had an increased risk for strokes
as well [5, 6]. Studies investigating the stroke risk in patients
with HFpEF in comparison to HFrEF have generally found a
similar stroke risk [41–45]. In contrast to HFpEF, the patients
with HFrEF have a higher mortality [44, 45]. Cogswell et al.
hypothesized a possible influence of undiagnosed (silent) par-
oxysmal AF on stroke risk in HFpEF patients, given that
stroke risk in patients with HFpEF without AF and HFpEF
with AF as well as AF-only was similar [5].
Silent Atrial fibrillation in HF
Atrial fibrillation is the most common cardiac arrhythmia [46]
and the strongest risk factor for the thromboembolic stroke
[10]. Because of a high prevalence of paroxysmal AF in pa-
tients with acute stroke [12], more extensive diagnostic ap-
proaches to reveal paroxysmal AF episodes are needed [47].
This is aggravated by the fact that one third of patients with
AF are not aware of its presence; hence, the term “silent AF”
has been introduced.
Silent AF is often discovered after serious cerebro- and
cardiovascular complications such as ischemic stroke and
HF via routine self-monitoring of the pulse, 12-lead electro-
cardiogram (ECG), 24-h Holter ECG [13], implanted pace-
makers, and defibrillators. In this context, attention has been
directed towards AF burden, defined by time spent in AF per
unit of time [48]. Several studies analyzing implanted devices
showed that 20–42% of HF patients have silent AF episodes
[49–51]. Silent AFwas also common (10%) at the acute phase
of ischemic stroke or transient ischemic attacks (TIAs) [52];
46% of patients suffering a cryptogenic stroke had silent AF
on continuous electrocardiographic monitoring [33]. Of note,
stroke incidence in silent AF is significantly higher in patients
with multiple risk factors, especially hypertension, advanced
age, obesity, diabetes mellitus, smoking, and previous cardiac
disease [53–55] and in those with higher CHA2DS2-VASc
score [56].
The presence of silent AF had been also described in pa-
tients with coronary artery disease and myocardial infarction
[57]. Turakhia et al. found a threefold higher rate of cardio-
vascular death and a fivefold higher rate of hospitalization for
HF in patients with silent AF [58]. In this context, silent AF
was also common after coronary artery bypass grafting (a
third had recorded AF episodes) [59]. The fact that silent AF
is a common finding in different populations leads to the as-
sumption that it could also play a role in stroke development in
HF patients.
Risk Stratification of Stroke in HF
Because of the high prevalence of HF in the population and
the associated stroke risk, there is interest in stroke prediction
and evaluation of the possible need of antithrombotic therapy
(Fig. 1).
The CHA2DS2-VASc score is widely used to estimate the
risk of stroke in AF patients and to help in decision-making
regarding oral anticoagulation [60]. In a nationwide prospec-
tive cohort of 42.987 patients with HF, Melgaard et al. dem-
onstrated that CHA2DS2-VASc score has also predictive pow-
er for stroke, regardless of AF presence [16••]. Similar results
have been found by Wolsk and colleagues in the Danish reg-
istry of 136,545 HF patients (with or without AF) [17] and in
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the WARCEF cohort [61]. The studies support consideration
of the CHA2DS2-VASc score for prediction of the risk of
stroke in HF irrespective of AF presence. Indeed, several stud-
ies examined the components of the CHA2DS2-VASc score
and demonstrated their individual association with stroke in
HF: congestive HF represented by a decreased ejection frac-
tion (hazard ratio [HR] 0.98–2.15) [15•, 34, 62, 63], hyperten-
sion (HR 1.18) [15•, 62, 64, 65], age (HR 1.34–1.35) [14, 15•,
62–64], diabetes mellitus (HR 1.114–1.87) [14, 15•, 16••, 62,
63, 65], prior stroke/TIA (HR 1.81–2.68) [14, 15•, 39, 63, 64],
vascular disease (HR 1.34) [66], and gender (HR 0.569) [15•,
62, 63]. In WARCEF sub-study with patients with sinus
rhythm, the ejection fraction was associated with stroke only
if its baseline values were less than 15% [62, 63].
However, the data are inconsistent. For example,
McMurray et al. did not find a correlation between ejection
fraction and stroke risk despite numerically higher rate of
stroke and systemic embolism in patients with left ventricular
systolic dysfunction [34]. Prior stroke [14, 15•, 39, 62, 64],
gender [15•], and also peripheral artery disease [66] are asso-
ciated with stroke risk in HF patients. Nevertheless, the cor-
relation between stroke risk and age [14, 15•, 64] in HF
patients as well as those with diabetes mellitus [15•, 16••,
65] and hypertension are conflicting [62].
Although there are many different scores predicting the
mortality in HF [67–69], the CHA2DS2-VASc score is the
only one shown to be useful for stroke prediction in HF.
Due to the lack of a convenient and accurate model to predict
stroke and the accompanied increased mortality in HF,
Freudenberger et al. proposed a new scoring system for stroke
prediction in patients with an ejection fraction of less 35%,
with a full model of their score, including 14 risk factors, and
to provide better clinical practicability a simpler more practi-
cal score of only eight of these components: age, blood oxy-
gen urea, ejection fraction, hemoglobin, gender, diastolic
blood pressure, diabetes mellitus, and prior stroke. In their
study population (n = 2305), the new developed score per-
formed modestly but was superior (statistically) to
CHA2DS2-VASc score in stroke prediction (area under the
curve [AUC] 0.660, 95% CI 0.58–0.74 vs 0.52, 95% CI
0.398–0.63, p = 0.001) [15•].
Several studies investigated the impact of renal function on
stroke risk in HF. Melgaard et al. showed an increased risk of
ischemic stroke and intracranial bleeding in HF patients with
stable chronic kidney disease, but this association could only
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Fig. 1 Risk factors for stroke in patients with heart failure. Abbreviations:
AF, atrial fibrillation; BMI, body mass index; NYHA class, New York
Heart Association class; TIA, transient ischemic attack; NT-proBNP, N-
terminal prohormone of brain natriuretic peptide; eGFR, estimated
glomerular filtration rate; Hb, hemoglobin
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be found in patients without renal replacement therapy [70].
These findings are in agreement with the results of another
study showing an association between estimated glomerular
filtration rate and stroke risk in HF patients [64].
Therapy
Given the increased risk of thromboembolic complications in
patients with HF, anticoagulation should be considered in
these patients also in the absence of AF. Nevertheless, current
guidelines do not recommend anticoagulation for patients
with HF in general [1].
Vitamin K Antagonists
There are four randomized clinical trials investigating the ef-
fect of Warfarin on stroke risk in patients with HF in compar-
ison to aspirin: WASH [21], HELAS [22], WATCH [23], and
WARCEF [71]. Details of the trials are summarized in
Table 1.
The WASH and HELAS trials were small studies, which
were underpowered but showed no suggestion for the efficacy
of anticoagulant therapy for HF patients in sinus rhythm [21,
22, 72]. The WATCH and WARCEF trials were larger studies
(with WARCEF being a double-blind trial) and showed no
significant benefit for the primary outcome that included mor-
tality but a significant risk reduction for stroke (a secondary
Table 1 Warfarin vs antiplatelet therapy in patients with sinus rhythm
WASH HELAS WATCH WARCEF
Year of
publication
2004 2006 2009 2012
Number of
patients
279 197 1587 2305
Treatment
arms
Aspirin vs warfarin
Placebo 99
Aspirin (300 mg) 91
Warfarin (INR 2–3) 89
Aspirin vs warfarin
Ischemic Heart disease: 61 Aspirin
(325 mg) 54 Warfarin (INR 2–3)
Dilatative cardiomyopathy: 38
Warfarin (INR 2–3) 44 Placebo
Aspirin/clopidogrel vs
warfarin 523
Aspirin (162 mg) 524
Clopidogrel (75 mg) 540
Warfarin (INR 2.5–3)
Aspirin vs warfarin 1163
Aspirin (325 mg) 1142
Warfarin (INR 2.5–3)
AF ca. 6% (baseline) None (exclusion criteria, patients
with AF in follow-up were
withdrawn)
10% (follow-up) ca. 4% (baseline)
Follow-up
(mean)
27 months ca. 20 months 21 months 3.5 years
Primary
endpoints
Composite of
(1) death
(2) non-fatal myocardial
infarction
(3) non-fatal stroke
Composite of
(1) non-fatal stroke
(2) peripheral or pulmonary
embolism
(3) myocardial (re)infarction
(4) re-hospitalization
(5) exacerbation of heart failure
(6) death from any cause
Composite of
(1) all-cause mortality
(2) non-fatal myocardial
infarction
(3) non-fatal stroke
Composite of
(1) ischemic stroke
(2) intracerebral hemorrhage
(3) death from any cause
Secondary
endpoints
(1) Death or cardiovascular
hospitalization (incl. major
hemorrhage)
(2) Death or all-cause
hospitalization
(3) Total number of
hospitalization
(4) Composite of death,
cardiovascular
hospitalization and increase
in diuretic therapy for
worsening heart failure
(1) Cardiac and total mortality
(2) Myocardial infarction or
re-infarction
(3) Heart failure exacerbation
(1) All-cause mortality
(2) Nonfatal myocardial
infarction
(3) Nonfatal stroke
(4) Hospitalization for
heart failure
Composite of
(1) primary outcome
(2) myocardial infarction
(3) hospitalization for heart failure
Safety
endpoints
Included in secondary
endpoints
Intracranial hemorrhage, incidence
of bleeding while on study drug,
differences in bleeding index on
study drug
Major bleeding Major bleeding, minor bleeding
Results Neither warfarin nor aspirin
reduces risk of stroke in
patients with HF
Neither warfarin nor aspirin reduced
risk of stroke in patients with HF
and without AF
Warfarin reduced stroke
more than aspirin or
clopidogrel but with a
higher risk of bleeding
Warfarin was superior to aspirin
concerning ischemic stroke but is
accompanied with higher rates of
intracerebral hemorrhages
Curr Heart Fail Rep
outcome) in patients treated with warfarin compared to aspi-
rin; however, the positive effect was neutralized by an in-
creased risk of major bleeding [23, 71]. In WATCH,
clopidogrel was superior neither to warfarin nor to aspirin
[23].
A meta-analysis of these four trials based on 3665 pa-
tients showed that warfarin reduced the risk of cardiovascu-
lar events including stroke by 20% compared to antiplatelet
therapy (risk ratio (RR) 0.79, 95% CI 0.63–1.00; I2 = 0%),
but the risk of major bleeding was twofold higher (RR 2.00,
95% CI 1.44–2.78; I2 = 4%). Consequently, the stroke risk
reduction of warfarin was outweighed by the increased
bleeding risk [73••]. Interestingly, there was no significant
increase of intracranial hemorrhage on warfarin compared to
antiplatelet therapy [74].
Non-Vitamin K Antagonists
The efficacy and safety of these anticoagulation drugs were
shown in AF patients in four randomized double-blind trials:
RE-LY, ARISTOTLE, ROCKET AF, and ENGAGE AF
[75–78].
In subgroup analyses, the effect of NOACs had been inves-
tigated in AF patients with and without HF (Table 2). In sum-
mary, NOACs (dabigatran [37], apixaban [34], or at least non-
inferior rivaroxaban [35] and edoxaban [36]) showed relative
efficacy and safety compared to warfarin; however, there were
no differences between patients with and without HF. Based
on these results, current HF management guidelines recom-
mend to prefer NOACs over warfarin in patients with con-
comitant HF and AF [1].
Table 2 Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and heart failure
Sub-studies RE-LY ARISTOTLE ROCKET-AF ENGAGE AF
Year of
publication
2013 2013 2013 2016
Number of
patients
18.113
4.904 with HF
13.209 without HF
14.671
3.207 with HF (EF > 40%)
2736 with HF (EF < 40%)
8728 without HF
14.171
9.033 with HF
5.138 without HF
14.071
6.344 HF HYHA I–II
1801 NYHA III–IV
5.926 without HF
Treatment
arms
Dabigatran vs warfarin Apixaban vs warfarin Rivaroxaban vs warfarin Edoxaban vs warfarin
Follow-up
(median)
2.0 years 18 months 707 days 2.8 years
Primary
endpoints
(1) Stroke (ischemic or
hemorrhagic)
(2) Systemic embolism
(1) Stroke (ischemic or
hemorrhagic)
(2) Systemic embolism
(1) Stroke (ischemic or
hemorrhagic)
(2) Noncentral nervous system
embolism
(1) Stroke (ischemic or
hemorrhagic)
(2) Systemic embolism
Secondary
endpoints
(1) Vascular death
(2) Hospitalization
(3) Intracranial bleeding
(4) Total bleeding
(1) Composite of
- Stroke
- Systemic embolism
- Death
(2) Net clinical benefit
composite of
- Stroke
- Systemic embolism
- Major bleeding
- Death from any cause
(1) All-cause death
(2) Myocardial infarction
(3) Composite of
- Stroke
- Systemic embolism
- Vascular death
(1) Ischemic stroke
(2) Hemorrhagic stroke
(3) Cardiovascular death
(4) Cardiovascular
hospitalization
(5) All-cause death
Safety
endpoints
Major bleeding Major bleeding (1) Primary: major or non-major
clinical relevant bleeding
(2) Secondary: intracranial
hemorrhage and hemorrhagic
stroke
Major bleeding
Results Dabigatran was superior to
warfarin concerning stroke
(annual rate 1.44 vs 1.92%)
and bleeding risk (annual rate
3.10 vs 3.90%). No
differences in efficacy and
safety between HF and
No-HF
Apixaban reduced risk for
stroke (HR 0.89, 95% CI
0.81–0.98)/bleeding/death
(HR 0.85, 95% CI 0.78–0.92)
more than warfarin
independently of presence of
HF
Rivaroxaban was non-inferior to
warfarin concerning efficacy
(HR 0.94, 95% CI 0.76–1.17)
and safety (HR 1.05, 95% CI
0.95–1.15) there was no
difference between HF and
No-HF
Edoxaban was non-inferior to
warfarin concerning efficacy
(stroke in no HF: HR 0.87,
95% CI 0.69–1.11, NYHA
III–IV: HR 0.83, 95% CI
0.55–1.25) and even more
safe (major bleeding in
no-HF: HR 0.82, 95% CI
0.68–0.99, NYHA III–IV:
HR 0.79, 95% CI 0.54–1.17),
there was no difference
between HF and No-HF
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A meta-analysis of RE-LY, ARISTOTLE, and ROCKET
AF including 19,122 subjects showed a significant risk reduc-
tion for stroke in patients with both HF and AF combined with
a decreased bleeding risk; in HF patients, NOACs were sim-
ilar effective or even safer compared to those without HF [79].
However, it remains unclear whether NOACs have a pos-
itive impact of stroke risk reduction in patients with HF but in
sinus rhythm. This question had been addressed in a random-
ized, double-blind, placebo-controlled trial (COMMANDER
HF) investigating the efficacy and safety of rivaroxaban vs
placebo in HF patients without AF, where HF is related to
ischemic heart disease and all patients are taking aspirin ther-
apy [80].
Current Approach
Based on RE-LY, ARISTOTLE, ROCKET AF, and
ENGAGE AF, European HF management guidelines
recommend anticoagulation in patients with both HF
and AF, with a preference for NOACs [1]. Because of
an increased bleeding risk outweighing the stroke risk
reduction using warfarin in patients with HF but without
AF [20–23, 71], the therapy of these patients needs to
be tailored to the individual risk profile (e.g., prior
stroke, cardiac thrombi) [1].
Conclusions
Based on the current evidence, HF should be considered as an
independent risk factor for stroke. The CHA2DS2-VASc score
might be useful to predict stroke risk in HF patients with or
without AF in clinical routine.
Thus far, there is only a recommendation for the oral
anticoagulation use in patients with concomitant HF and AF,
while in patients with HF and no AF, individualized risk strat-
ification is preferred. Based on recent data, NOACs should be
preferred over warfarin. Finally, the results of ongoing studies
may clarify further aspects of anticoagulation in HF patients
without AF.
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